Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial

IMPORTANCE: Faricimab neutralizes angiopoietin-2 and vascular endothelial growth factor A via both simultaneous and independent binding. OBJECTIVE: To evaluate extended dosing with faricimab, the first bispecific antibody designed for intraocular use, in patients with neovascular age-related macular...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanani, Arshad M., Patel, Sunil S., Ferrone, Philip J., Osborne, Aaron, Sahni, Jayashree, Grzeschik, Susanna, Basu, Karen, Ehrlich, Jason S., Haskova, Zdenka, Dugel, Pravin U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489851/
https://www.ncbi.nlm.nih.gov/pubmed/32729897
http://dx.doi.org/10.1001/jamaophthalmol.2020.2699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489851/
https://www.ncbi.nlm.nih.gov/pubmed/32729897
http://dx.doi.org/10.1001/jamaophthalmol.2020.2699

Ejemplares similares